Equity Profile

INCY

Incyte Corporation

Health CareBiotechnology$24.4B

Jul28Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Incyte Corporation (INCY) is a biotechnology company focused on discovering, developing, and commercializing innovative medicines, primarily for cancer treatment. With a market cap of $24 billion, Incyte plays a significant role in the health care sector, particularly in oncology, which is a major area of medical research and investment.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

INCY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-36.50%

Avg Stock Reaction

+0.90%

Last Quarter Recap

In Q1 2026, Incyte reported an EPS of $1.81, significantly beating estimates by 58.77%. The stock reacted positively, gaining 2.12% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Incyte has shown strong EPS surprises in recent quarters, but revenue data remains unclear. Investors are eager to see if this trend continues.

Bull Case

If Incyte continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant decline in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's strong EPS surprises in recent quarters, this number will be critical for investor sentiment and stock performance.

What guidance will management provide for revenue growth?

Investors will be looking for clear signals on future revenue growth, which is essential for assessing the company's long-term prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Incyte's ability to sustain high EPS growth, given its recent performance and market position.

Supporting Evidence

Incyte has beaten EPS estimates in 75% of the last eight quarters, indicating a strong operational track record.

The options market is pricing a larger move than historical averages, suggesting heightened expectations that may not be justified.

Key Risk

If the EPS comes in below $1.50, it could significantly undermine confidence in the company's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Incyte can maintain its strong earnings performance amid uncertain revenue trends.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.50 would confirm the bear case, suggesting potential operational issues.

Pre-Earnings Positioning

Options Market

Implied Move

±15.51%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±15.5% while INCY has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

23.4%

Calls (7K)P/C Ratio: 0.07Puts (57K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Incyte beats expectations, history suggests the stock could rise by around 1.13%, confirming strong operational health.

In-Line / Cautious

If results are in line but cautious, the stock may see muted movement as investors digest the commentary.

Miss

A miss could lead to a decline of about 0.18%, reflecting disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or clinical trial results.
2Management's commentary on market conditions and competitive landscape.
3Insights into cost management and operational efficiency.
4Guidance on future revenue growth and market expansion plans.
5Details on any strategic partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

INCY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-36.50%

Avg Stock Reaction

+0.90%

Last Quarter Recap

In Q1 2026, Incyte reported an EPS of $1.81, significantly beating estimates by 58.77%. The stock reacted positively, gaining 2.12% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Incyte has shown strong EPS surprises in recent quarters, but revenue data remains unclear. Investors are eager to see if this trend continues.

Bull Case

If Incyte continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant decline in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's strong EPS surprises in recent quarters, this number will be critical for investor sentiment and stock performance.

What guidance will management provide for revenue growth?

Investors will be looking for clear signals on future revenue growth, which is essential for assessing the company's long-term prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Incyte's ability to sustain high EPS growth, given its recent performance and market position.

Supporting Evidence

Incyte has beaten EPS estimates in 75% of the last eight quarters, indicating a strong operational track record.

The options market is pricing a larger move than historical averages, suggesting heightened expectations that may not be justified.

Key Risk

If the EPS comes in below $1.50, it could significantly undermine confidence in the company's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Incyte can maintain its strong earnings performance amid uncertain revenue trends.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.50 would confirm the bear case, suggesting potential operational issues.

Pre-Earnings Positioning

Options Market

Implied Move

±15.51%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±15.5% while INCY has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

23.4%

Calls (7K)P/C Ratio: 0.07Puts (57K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Incyte beats expectations, history suggests the stock could rise by around 1.13%, confirming strong operational health.

In-Line / Cautious

If results are in line but cautious, the stock may see muted movement as investors digest the commentary.

Miss

A miss could lead to a decline of about 0.18%, reflecting disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or clinical trial results.
2Management's commentary on market conditions and competitive landscape.
3Insights into cost management and operational efficiency.
4Guidance on future revenue growth and market expansion plans.
5Details on any strategic partnerships or collaborations.